Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00p -3.92% 24.50p 343,192 12:21:46
Bid Price Offer Price High Price Low Price Open Price
24.00p 25.00p 25.50p 24.50p 25.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.85 -2.53 -0.40 63.5

Kromek (KMK) Latest News

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
20/11/201815:40Kromek Group PLC2,460
21/8/201709:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-11-20 15:40:2324.0031,9507,668.01O
2018-11-20 13:18:2724.788,0711,999.99O
2018-11-20 12:21:5924.1540,1269,690.43O
2018-11-20 11:56:2125.2015037.80O
2018-11-20 11:51:3925.1010,0002,510.00O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
20/11/2018
08:20
Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 25.50p.
Kromek has a 4 week average price of 22.10p and a 12 week average price of 22.10p.
The 1 year high share price is 31.65p while the 1 year low share price is currently 18.80p.
There are currently 259,015,618 shares in issue and the average daily traded volume is 287,476 shares. The market capitalisation of Kromek is £63,458,826.41.
03/7/2018
11:32
pastybap: That's Simon Thompson having an effect on the share price. ST clearly holds more weight than that numpty!
05/6/2018
14:09
chimers: Walbrock’s opinions on Kromek Kromek business is growing and will likely break even on EBITDA, but on EBIT you will have to wait beyond 2020. Meanwhile, development costs (capitalized expenses) have risen to £11.6m in 2017 and will rise further. The question investor should ask: “Will the company’s valuation and share price survive when cash balance starts to fall?” On that basis, I’m leaning towards that the share price will remain under pressure because of the amount of time it will make a profit.
02/5/2018
13:58
chimers: All courtesy of Walbrock who seem to "get" it. "Walbrock’s opinions on Kromek Kromek business is growing and will likely break even on EBITDA, but on EBIT you will have to wait beyond 2020. Meanwhile, development costs (capitalised expenses) have risen to £11.6m in 2017 and will rise further. The question investor should ask: “Will the company’s valuation and share price survive when cash balance starts to fall?” On that basis, I’m leaning towards that the share price will remain under pressure because of the amount of time it will make a profit."
01/5/2018
13:24
chimers: Awwww well.................not to worry eh!! Walbrock’s opinions on Kromek Kromek business is growing and will likely break even on EBITDA, but on EBIT you will have to wait beyond 2020. Meanwhile, development costs (capitalized expenses) have risen to £11.6m in 2017 and will rise further. The question investor should ask: “Will the company’s valuation and share price survive when cash balance starts to fall?” On that basis, I’m leaning towards that the share price will remain under pressure because of the amount of time it will make a profit.
01/5/2018
13:19
walbrock82: Looking at Kromek, I see their business is growing and will likely break even on EBITDA as forecasted, but on an EBIT basis, you will have to wait beyond 2020. Meanwhile, development costs (capitalised expenses) have risen to £11.6m in 2017 and will rise further. The question investor should ask: “Will the company’s valuation and share price survive when cash balance starts to fall?” On that basis, I’m leaning towards that the share price remains under pressure because of the amount of time it will make a profit. For more on Kromek and a look at Connect Group, click http://bit.ly/2JK9GK7
22/12/2017
11:05
walbrock82: Kromek still needs to prove themselves they are a viable business. The latest management update looks positive, but we need them to deliver. I know they have been securing contracts and increasing their order book. It's whether they will make a profit from these contracts that would benefit shareholders. Otherwise, it is enough to pay their bills and staff, including management. The next few years are critical for Kromek's management because it will determine if the share price could potentially double in value or collapse by 80%. I wish shareholders for the best. If you want to read the interpretation of Kromek's financial accounts for the past six years, it is here: http://bit.ly/2kXBlfX
07/12/2017
15:59
mesquida: Funny how Chimers only posts on days when the share price is down.
15/11/2017
16:01
glawsiain: Heres the text from telegraph for what its worth: "On the face of it, our suggestion that readers buy shares in Kromek, the Aim-listed maker of advanced detection equipment, has not gone well. We first tipped the shares at 27p in March, and reiterated the advice at 29.75p in May, and at 26.63p the following month. At 23.25p last night, readers who took our advice are sitting on paper losses of 13.9pc, 21.8pc and 12.7pc respectively. But this is a case where it looks as though the market may have got it wrong – something that is more likely in the case of a small stock such as Kromek. Various factors can cause the market to misprice a small business, ranging from technical devices such as stop-losses to simple impatience on the part of investors. Gervais Williams, a respected investor in smaller companies, who holds Kromek in his Miton UK Smaller Companies fund, said that because there hadn’t been much upward momentum in the share price, even a small amount of trading in the stock could move the price. “To some degree this can be self-fulfilling in the short term,” he said, pointing out that some recent falls “will have triggered a few stop-loss limits for some small holders”, leading to more selling. He said disposals by another fund management firm might also have been a cause of recent weakness. Williams added: “The key fundamental is that we are all excited about the potential orders for Kromek’s products, and if these announcements take a while to arrive then the market gets a bit bored. The lack of momentum does leave the share price at risk after a short-term spike. "I suspect we will see an institutional investor stepping in at some stage to see if there is any real volume of stock about. I don’t think there is, and after a few days, all things being equal, I assume the price will revert to where it was previously.” Currently the shares are flirting with record lows close to 20p. If Williams is right about the trading dynamics, we can perhaps expect them to return closer to 30p – which would of course represent a substantial increase. Ultimately, though, Questor is more interested in companies that have good products and can sell them profitably than in the day-to-day moods of the stock market. In this respect, Williams is unworried. “Am I holding? You bet,” he said. “In terms of conviction in the company I’m not the least bit bothered.” Readers can also take some reassurance from the fact that there has been some small-scale buying by Kromek’s directors at the depressed share prices of recent weeks. Questor says: buy Ticker: KMK Share price at close: 23.25p"
19/6/2017
18:55
chimers: If you subscribe to the Investors Chronicle you will get live info like this which is now a week old. " Funded for explosive growth Another good example is Sedgefield-based Kromek (KMK:31.5p), a radiation detection technology company focused on the medical, security and nuclear markets. I had been patiently monitoring the company for some time, noting a raft of contract wins, but what prompted me to recommend buying the Aim-traded shares at 25p in late February was news of an oversubscribed placing and open offer which raised £20m ('Follow the smart money', 27 Feb 2017). It was an unusual fundraise as Kromek didn't need the money, but tapped shareholders to strengthen its position when negotiating contracts with government bodies and original equipment manufacturer (OEM) customers who had concerns about the company's financial strength and ability to supply significant quantities of its core cadmium zinc telluride (CZT) technologies. It's a hot area to be operating in given the geopolitical backdrop and heightened risk of terrorism. In fact, Kromek revealed this week that its next generation standalone radiation detector was deployed by the European Commission Counter Terrorism Unit during the NATO Security Summit and the visit to Brussels last month of US President, Donald Trump. It's a strong stamp of approval for the company's technology and can only be supportive of Kromek's revenues ramping up sharply as more potential customers sign on the dotted line. Bearing this in mind, although analysts Hannah Crowe and Paul Hill at research firm Equity Development predict Kromek can lift revenues by more than a third to £12.5m in the financial year to end April 2018, prompting a move into cash profitability, only £2.24m of this sum is dependent on new shipments. That's because £7.2m of the £12.5m revenue forecast is backed fully by a flow-through of the order book, and a further £3m is supported by repeat or expected orders. It wouldn't take many new contracts to accelerate the move into profitability. Reassuringly, while I was on annual leave, Kromek announced in a pre-close trading update that "products continue to gain traction in all our business segments from the increasing adoption of CZT-based technology and other products. The company expects to continue to win new customers and, together with the momentum of contract wins, it expects a step change in revenue growth in the new financial calendar year." Equity Development's forecasts look on the money to me. In the circumstances, it's hardly surprising that Kromek's share price subsequently hit my 34p target price. That was the cue for some profit taking, but after consolidating gains the share price looks well placed once again to achieve that discounted cash-flow-based target price. Rated on 1.8 times book value of £44m, and with pro-forma net cash of £22m equating to 8.5p a share. I would run profits ahead of next month's results."
12/4/2017
06:34
hyperboreus: Not wishing to comment on anything that has gone before but ST did in fact reply yesterday to patient_investor regarding Kromek in his comments section basically just reiterating his current stance on the Company: 1:17 PM on 11/4/2017 Hi Simon, Please could you provide your thoughts on KMK share price returning to 26.40p, a fall of some 30% since their inevitable spike in the aftermath of your tip? Do you still rate the shares a "strong buy"? Regards Patient SIMONTHOMPSON 1:36 PM on 11/4/2017 Patient I advised buying Kromek shares at 25p on Monday, 27 February after which almost 12 million shares traded in 689 bargains in the following two days. The weight of money continued to chase the shares and this meant that the share price moved up 36 per cent from 25.5p on the offer at 12pm on Monday 27 February to a high of 34.9p on Tuesday 7 March. In my analysis I stated that: "From my lens, the bottom is now in place and a break-out above the 25p resistance is highly likely, suggesting a sharp move to the 30p resistance level that halted progress last summer. Beyond that analyst's 34p a share price targets come firmly into play." I can't blame anyone for taking a 36 per cent profit in the space of a week. I would also mention that the Daily Telegraph subsequently tipped the shares which accentuated the rise and a fair amount of that buying was hot money, hence the subsequent fall. Nothing has changed in terms of the investment case as I still believe that 34p a share is fair value. I would flag up that subsequent to my article, on 24 March 2017, Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares at a price of 29.35 pence per share. Also, Kromek has also been awarded a contract, valued at $990k, by an existing US-based customer, a global leader in aerospace and defence technologies, for the upgrade of the Company's advanced security screening detectors that the customer has deployed since 2009. I believe the shares rate a buy at 26p. I hope this clarifies matters. Best wishes
Kromek share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181121 02:41:56